{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:30:26Z","timestamp":1787574626673,"version":"build-2736575974"},"reference-count":100,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Biotherapeutics are medicinal agents derived from or related to naturally occurring molecules in the body and are designed to modulate specific immune targets. This review examines clinically established biologics and targeted small molecules that affect cytokine-driven transcriptional programs, principally JAK\/STAT and canonical and non-canonical NF-\u03baB signaling, across autoimmune, neoplastic, hematological, dermatological, and rheumatic diseases. Periodontitis is used as a translational model because dysbiotic mucosal inflammation, cytokine signaling, and osteoclastogenesis may also intersect with systemic autoimmunity. In particular, Porphyromonas gingivalis-associated protein citrullination provides a plausible link to anti-citrullinated protein antibody-positive rheumatoid arthritis in genetically susceptible individuals, although causality remains unproven. The review also evaluates plant-derived modulators of JAK\/STAT and related transcriptional pathways. Curcumin and resveratrol have entered small rheumatoid arthritis studies, whereas evidence for catechins, celastrol, and artemisinin derivatives in autoimmune disease remains predominantly preclinical. These compounds may inform adjunctive or locally delivered strategies, but clinical translation requires better target selectivity, bioavailability, dose standardization, and safety data.<\/jats:p>","DOI":"10.3390\/jcm15176523","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:47:19Z","timestamp":1787572039000},"page":"6523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced Biological Therapies: Principles, Mechanisms and Medical Applications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0917-9214","authenticated-orcid":false,"given":"Rafal","family":"Brozek","sequence":"first","affiliation":[{"name":"Department of Prosthodontics and Geriatric Dentistry, Poznan University of Medical Sciences, 60-812 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-3621","authenticated-orcid":false,"given":"Antonina","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Reproductive Biology and Stem Cells, Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-7761","authenticated-orcid":false,"given":"Barbara","family":"Dorocka-Bobkowska","sequence":"additional","affiliation":[{"name":"Department of Prosthodontics and Geriatric Dentistry, Poznan University of Medical Sciences, 60-812 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-3245","authenticated-orcid":false,"given":"Maciej","family":"Kurpisz","sequence":"additional","affiliation":[{"name":"Department of Reproductive Biology and Stem Cells, Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"ref_1","unstructured":"U.S. Food and Drug Administration (2026, August 12). What Are \u201cBiologics\u201d Questions and Answers, Available online: https:\/\/www.fda.gov\/about-fda\/center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/rheumatology\/key207","article-title":"The British Society for Rheumatology Biologic DMARD Safety Guidelines in Inflammatory Arthritis\u2014Executive Summary","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"ref_3","unstructured":"Cooper, G.M. (2000). Signaling Molecules and Their Receptors. The Cell: A Molecular Approach, Sinauer Associates. [2nd ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-024-01888-z","article-title":"Cell-Cell Communication: New Insights and Clinical Implications","volume":"9","author":"Su","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sever, R., and Brugge, J.S. (2015). Signal Transduction in Cancer. Cold Spring Harb. Perspect. Med., 5.","DOI":"10.1101\/cshperspect.a006098"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2249.2006.03261.x","article-title":"Chronic Inflammation: Importance of NOD2 and NALP3 in Interleukin-1beta Generation","volume":"147","author":"Nielsen","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"ref_7","first-page":"3418975","article-title":"Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv. Pharmacol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar4174","article-title":"Use of NSAIDs in Treating Patients with Arthritis","volume":"15","author":"Crofford","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115327","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A Panoramic Review of IL-6: Structure, Pathophysiological Roles and Inhibitors","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 Family in Innate Inflammation and Acquired Immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1439","article-title":"The Adaptor Act1 Is Required for Interleukin 17-Dependent Signaling Associated with Autoimmune and Inflammatory Disease","volume":"8","author":"Qian","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Godoi, M.A., Camilli, A.C., Gonzales, K.G.A., Costa, V.B., Papathanasiou, E., Leite, F.R.M., and Guimar\u00e3es-Stabili, M.R. (2023). JAK\/STAT as a Potential Therapeutic Target for Osteolytic Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210290"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0022034521995157","article-title":"Host Modulation and Treatment of Periodontal Disease","volume":"100","author":"Balta","year":"2021","journal-title":"J. Dent. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, Z., Lang, G., Xu, X., Liang, X., Han, Y., and Han, Y. (2024). The Role of NF-kappaB in the Inflammatory Processes Related to Dental Caries, Pulpitis, Apical Periodontitis, and Periodontitis\u2014A Narrative Review. PeerJ, 12.","DOI":"10.7717\/peerj.17953"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/prd.12331","article-title":"Current Understanding of Periodontal Disease Pathogenesis and Targets for Host-Modulation Therapy","volume":"84","author":"Hajishengallis","year":"2000","journal-title":"Periodontology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1002\/JPER.18-0006","article-title":"Staging and Grading of Periodontitis: Framework and Proposal of a New Classification and Case Definition","volume":"89","author":"Tonetti","year":"2018","journal-title":"J. Periodontol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/art.27552","article-title":"Peptidylarginine Deiminase from Porphyromonas Gingivalis Citrullinates Human Fibrinogen and \u03b1-Enolase: Implications for Autoimmunity in Rheumatoid Arthritis","volume":"62","author":"Wegner","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.39491","article-title":"Antibodies to Porphyromonas Gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology","volume":"68","author":"Kharlamova","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.38348","article-title":"Periodontitis and Porphyromonas Gingivalis in Patients with Rheumatoid Arthritis","volume":"66","author":"Mikuls","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"369ra176","DOI":"10.1126\/scitranslmed.aaj1921","article-title":"Aggregatibacter Actinomycetemcomitans-Induced Hypercitrullination Links Periodontal Infection to Autoimmunity in Rheumatoid Arthritis","volume":"8","author":"Konig","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Singh, J.A., Shah, N.P., and Mudano, A.S. (2021). Belimumab for Systemic Lupus Erythematosus. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD010668.pub2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: A Review in Ankylosing Spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A Road Map for Those Who Don\u2019t Know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1756-8722-6-90","article-title":"STAT Inhibitors for Cancer Therapy","volume":"6","author":"Furqan","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Molenda, S., Sikorska, A., Florczak, A., Lorenc, P., and Dams-Kozlowska, H. (2023). Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer-Drug Carriers Matter. Cancers, 15.","DOI":"10.3390\/cancers15235647"},{"key":"ref_29","unstructured":"European Medicines Agency (2026, August 12). Janus Kinase Inhibitors (JAKi)\u2014Referral. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (2026, August 12). FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical Use of Anti-TNF Therapy and Increased Risk of Infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of Developing Tuberculosis Under Anti-TNF Treatment Despite Latent Infection Screening","volume":"7","author":"Turon","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF-Alpha Therapy in Rheumatoid Arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-Alpha: Structure, Function and Interaction with Anti-TNF Agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gardam, S., and Brink, R. (2014). Non-Canonical NF-\u03baB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00509"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kaegi, C., Wuest, B., Schreiner, J., Steiner, U.C., Vultaggio, A., Matucci, A., Crowley, C., and Boyman, O. (2019). Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01990"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab Reduces Autoantibodies, Normalizes Low Complement Levels, and Reduces Select B Cell Populations in Patients with Systemic Lupus Erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: Regulator of Treg\/Th17 Balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an Interleukin-17A Antagonist in the Treatment of Ankylosing Spondylitis or Radiographic Axial Spondyloarthritis in Patients Previously Untreated with Biological Disease-Modifying Anti-Rheumatic Drugs (COAST-V): 16 Week Results of a Phase 3 Randomised, Double-Blind, Active-Controlled and Placebo-Controlled Trial","volume":"392","author":"Dougados","year":"2018","journal-title":"Lancet"},{"key":"ref_40","unstructured":"European Medicines Agency (2026, August 12). Orencia. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orencia."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Loh, C.-Y., Arya, A., Naema, A.F., Wong, W.F., Sethi, G., and Looi, C.Y. (2019). Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00048"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sgrignani, J., Garofalo, M., Matkovic, M., Merulla, J., Catapano, C.V., and Cavalli, A. (2018). Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061591"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.tips.2019.03.001","article-title":"Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease","volume":"40","author":"Durham","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1101\/gad.1553707","article-title":"Unphosphorylated STAT3 Accumulates in Response to IL-6 and Activates Transcription by Binding to NF\u03baB","volume":"21","author":"Yang","year":"2007","journal-title":"Genes Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1038\/s41467-019-10970-y","article-title":"A Molecular Switch from STAT2\u2013IRF9 to ISGF3 Underlies Interferon-Induced Gene Transcription","volume":"10","author":"Platanitis","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 Phosphorylates Histone H3Y41 and Excludes HP1\u03b1 from Chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1171721","article-title":"Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation","volume":"324","author":"Gough","year":"2009","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1038\/sj.onc.1210092","article-title":"Engagement of the B-Cell Antigen Receptor Activates STAT through Lyn in a JAK-Independent Pathway","volume":"26","author":"Wang","year":"2007","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(00)80402-1","article-title":"MyD88: An Adapter That Recruits IRAK to the IL-1 Receptor Complex","volume":"7","author":"Wesche","year":"1997","journal-title":"Immunity"},{"key":"ref_51","unstructured":"Ahmad, A., Zaheer, M., and Balis, F.J. (2025). Baricitinib. StatPearls, StatPearls Publishing."},{"key":"ref_52","unstructured":"Haq, M., and Adnan, G. (2025). Ruxolitinib. StatPearls, StatPearls Publishing."},{"key":"ref_53","unstructured":"Padda, I.S., Bhatt, R., and Parmar, M. (2025). Tofacitinib. StatPearls, StatPearls Publishing."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"ref_55","unstructured":"Padda, I.S., Bhatt, R., Patel, P., and Parmar, M. (2025). Upadacitinib. StatPearls, StatPearls Publishing."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with up to 4 Years of Exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a Newly Approved Treatment for Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib Versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): An International, Randomised, Phase 3 Trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2018.06.014","article-title":"Phase 2 Study of Gandotinib (LY2784544) in Patients with Myeloproliferative Neoplasms","volume":"71","author":"Berdeja","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2017.08.010","article-title":"A Phase 1 Study of the Janus Kinase 2 (JAK2)V617F Inhibitor, Gandotinib (LY2784544), in Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia","volume":"61","author":"Verstovsek","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.114.221176","article-title":"VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor that Attenuates Inflammation in Animal Models of Autoimmune Disease","volume":"353","author":"Mahajan","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients with Active Rheumatoid Arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40744-019-00167-6","article-title":"Two-Year Safety and Effectiveness of Peficitinib in Moderate-to-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study","volume":"6","author":"Genovese","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized Controlled Trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaad.2023.04.027","article-title":"Oral Spleen Tyrosine Kinase\/Janus Kinase Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study","volume":"89","author":"Jimenez","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The Oral Janus Kinase\/Spleen Tyrosine Kinase Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Double-Blind Placebo-Controlled Study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15071","DOI":"10.1038\/cddiscovery.2015.71","article-title":"Resveratrol and STAT Inhibitor Enhance Autophagy in Ovarian Cancer Cells","volume":"2","author":"Zhong","year":"2016","journal-title":"Cell Death Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.180.9.6193","article-title":"T Cell Response Mediated by Myeloid Cell-Derived IL-12 Is Responsible for Porphyromonas Gingivalis-Induced Periodontitis in IL-10-Deficient Mice","volume":"180","author":"Sasaki","year":"2008","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/0022034516645332","article-title":"SOCS-3 Regulates Alveolar Bone Loss in Experimental Periodontitis","volume":"95","author":"Papathanasiou","year":"2016","journal-title":"J. Dent. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2019.12.003","article-title":"Efficacy of Baricitinib on Periodontal Inflammation in Patients with Rheumatoid Arthritis","volume":"87","author":"Mihailov","year":"2020","journal-title":"Jt. Bone Spine"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kobayashi, T., Ito, S., Murasawa, A., Ishikawa, H., and Yoshie, H. (2019). Effects of Tofacitinib on the Clinical Features of Periodontitis in Patients with Rheumatoid Arthritis: Two Case Reports. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0062-y"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/154405910808701002","article-title":"IL-6 Induces Osteoblastic Differentiation of Periodontal Ligament Cells","volume":"87","author":"Iwasaki","year":"2008","journal-title":"J. Dent. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-0765.2007.00977.x","article-title":"Osteogenic Effect of Interleukin-11 and Synergism with Ascorbic Acid in Human Periodontal Ligament Cells","volume":"42","author":"Leon","year":"2007","journal-title":"J. Periodontal Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1590\/S1678-77572012000200002","article-title":"Modulation of Host Cell Signaling Pathways as a Therapeutic Approach in Periodontal Disease","volume":"20","author":"Rossa","year":"2012","journal-title":"J. Appl. Oral Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2174\/1568026616666160212122820","article-title":"Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma","volume":"16","author":"Ilamathi","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","article-title":"Green Tea Catechin, Epigallocatechin-3-Gallate (EGCG): Mechanisms, Perspectives and Clinical Applications","volume":"82","author":"Singh","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Casc\u00e3o, R., Fonseca, J.E., and Moita, L.F. (2017). Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00069"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/ptr.4639","article-title":"A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis","volume":"26","author":"Chandran","year":"2012","journal-title":"Phytother. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s10067-018-4080-8","article-title":"Resveratrol as an Effective Adjuvant Therapy in the Management of Rheumatoid Arthritis: A Clinical Study","volume":"37","author":"Khojah","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12950-015-0097-9","article-title":"Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-like 2 Antioxidant Pathway","volume":"12","author":"Min","year":"2015","journal-title":"J. Inflamm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.autrev.2012.02.022","article-title":"Effective Treatment of Rat Adjuvant-Induced Arthritis by Celastrol","volume":"11","author":"Vidal","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/cmi.2009.58","article-title":"A Pilot Study of the Therapeutic Efficacy and Mechanism of Artesunate in the MRL\/lpr Murine Model of Systemic Lupus Erythematosus","volume":"6","author":"Jin","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The Non-Canonical NF-\u03baB Pathway in Immunity and Inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1902\/jop.2005.76.7.1148","article-title":"Expression of Activated Transcription Factor Nuclear Factor-kappaB in Periodontally Diseased Tissues","volume":"76","author":"Ambili","year":"2005","journal-title":"J. Periodontol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12951-021-01175-x","article-title":"Remodeling Immune Microenvironment in Periodontitis Using Resveratrol Liposomes as an Antibiotic-Free Therapeutic Strategy","volume":"19","author":"Shi","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/JPER.23-0543","article-title":"Human Gingival Fibroblasts Are a Source of B Cell-Activating Factor During Periodontal Inflammation","volume":"95","author":"Dyab","year":"2024","journal-title":"J. Periodontol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhang, T., Zhang, Z., Wang, Z., Zhou, Y.-J., and Wang, Z. (2021). B Cell Activating Factor Regulates Periodontitis Development by Suppressing Inflammatory Responses in Macrophages. BMC Oral Health, 21.","DOI":"10.1186\/s12903-021-01788-6"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jre.12696","article-title":"LIPUS Inhibited the Expression of Inflammatory Factors and Promoted the Osteogenic Differentiation Capacity of hPDLCs by Inhibiting the NF-\u03baB Signaling Pathway","volume":"55","author":"Liu","year":"2020","journal-title":"J. Periodontal Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"119042","DOI":"10.1016\/j.bbamcr.2021.119042","article-title":"Visfatin Regulates Pg LPS-Induced Proinflammatory\/Prodegradative Effects in Healthy and Inflammatory Periodontal Cells Partially via NF-\u03baB Pathway","volume":"1868","author":"Yao","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/00220345211019689","article-title":"LncRNA Nron Inhibits Bone Resorption in Periodontitis","volume":"101","author":"Li","year":"2022","journal-title":"J. Dent. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.molimm.2018.05.008","article-title":"MicroRNA-21 Down-Regulates Inflammation and Inhibits Periodontitis","volume":"101","author":"Zhou","year":"2018","journal-title":"Mol. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1101\/gad.11.24.3482","article-title":"Requirement for NF-kappaB in Osteoclast and B-Cell Development","volume":"11","author":"Franzoso","year":"1997","journal-title":"Genes Dev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1210\/en.2010-0399","article-title":"Suppression of NF-kappaB Increases Bone Formation and Ameliorates Osteopenia in Ovariectomized Mice","volume":"151","author":"Alles","year":"2010","journal-title":"Endocrinology"},{"key":"ref_96","first-page":"4517","article-title":"Calcium Phosphate-Based Materials Regulate Osteoclast-Mediated Osseointegration","volume":"6","author":"Wang","year":"2021","journal-title":"Bioact. Mater."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Aoki, T., Hiura, F., Li, A., Yang, N., Takakura-Hino, N., Mukai, S., Matsuda, M., Nishimura, F., and Jimi, E. (2023). Inhibition of Non-Canonical NF-\u03baB Signaling Suppresses Periodontal Inflammation and Bone Loss. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1179007"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wang, J., Wang, B., Lv, X., and Wang, L. (2020). NIK Inhibitor Impairs Chronic Periodontitis via Suppressing Non-Canonical NF-\u03baB and Osteoclastogenesis. Pathog. Dis., 78.","DOI":"10.1093\/femspd\/ftaa045"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Song, J., Kwon, S.-H., Wang, Z., Park, S.-G., Piao, X., Ryu, J.-H., Kim, N., Kim, O.-S., and Kim, S.-H. (2023). Pirfenidone Inhibits Alveolar Bone Loss in Ligature-Induced Periodontitis by Suppressing the NF-\u03baB Signaling Pathway in Mice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108682"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"20790","DOI":"10.1002\/jcp.28685","article-title":"Transcription Factor 7-like 2-Associated Signaling Mechanism in Regulating Cementum Generation by the NF-\u03baB Pathway","volume":"234","author":"Zhao","year":"2019","journal-title":"J. Cell. Physiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:09:38Z","timestamp":1787573378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":100,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176523"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176523","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}